Serum neurofilament light chain as a preclinical marker of neurodegeneration

Volume: 18, Issue: 12, Pages: 1070 - 1071
Published: Dec 1, 2019
Abstract
To date, most clinical trials of disease-modifying drugs for neurodegenerative diseases, namely Alzheimer's disease, have been unsuccessful, mainly due to the inclusion of patients with too advanced disease. 1 Honig LS Vellas B Woodward M et al. Trial of solanezumab for mild dementia due to Alzheimer's Disease. N Engl J Med. 2018; 378: 321-330 Crossref PubMed Scopus (565) Google Scholar One explanation is that, once the pathophysiological...
Paper Details
Title
Serum neurofilament light chain as a preclinical marker of neurodegeneration
Published Date
Dec 1, 2019
Volume
18
Issue
12
Pages
1070 - 1071
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.